Zobrazeno 1 - 10
of 65
pro vyhledávání: '"C Andrew DeRyke"'
Publikováno v:
BMC Microbiology, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Carbapenem-resistant bacteria are an increasing problem in clinical practice; thus, it is important to identify β-lactamase inhibitors (e.g., relebactam) that can restore carbapenem susceptibility. We report analyses of relebacta
Externí odkaz:
https://doaj.org/article/08451fadbc924794b4696c967675da02
Autor:
James A. Karlowsky, Sibylle H. Lob, Tsz K. Khan, Wei-Ting Chen, Patrick C.Y. Woo, Wing Hong Seto, Margaret Ip, Stanley W.M. Leung, Queenie W.-L. Wong, Rene W.Y. Chau, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 33, Iss , Pp 260-266 (2023)
ABSTRACT: Objectives: The aim of this study was to estimate carbapenem resistance in Pseudomonas aeruginosa and Enterobacterales isolated from infected patients in intensive care unit (ICU) and non-ICU hospital wards in Hong Kong. Methods: Isolates o
Externí odkaz:
https://doaj.org/article/86aee0f92e2846ffb07064080af0c063
Autor:
Sibylle H. Lob, Mark A. Estabrook, C. Andrew DeRyke, Irina Alekseeva, Fakhar Siddiqui, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Publikováno v:
International Journal of Infectious Diseases, Vol 125, Iss , Pp 250-257 (2022)
Objectives: We evaluated the activity of ceftolozane/tazobactam (C/T), and comparators against clinical Pseudomonas aeruginosa isolates collected for the global Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program in ten
Externí odkaz:
https://doaj.org/article/0f3e5fee3733454da0f7846a3cd6b3de
Autor:
James A. Karlowsky, Sibylle H. Lob, Fakhar Siddiqui, Jacqueline Pavia, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 27, Iss 3, Pp 102775- (2023)
Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa are being isolated from patient specimens with increasing frequency in Latin America and worldwide. The current study provides an initial description of the in vitro activity of imipene
Externí odkaz:
https://doaj.org/article/a0da972580054cb2a31020aeecfd37f4
Autor:
Sibylle H. Lob, Krystyna M. Kazmierczak, Wei-Ting Chen, Fakhar Siddiqui, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 29, Iss , Pp 527-533 (2022)
Objectives: Antimicrobial resistance is one of the top 10 global public-health threats. Especially high rates of resistance have been reported for isolates from ICU patients, requiring expanded treatment options in this setting. We evaluated the acti
Externí odkaz:
https://doaj.org/article/4a683a0e7cbc4207acf33beb6204a569
Autor:
Michael A. Pfaller, Dee Shortridge, Kelly A. Harris, Mark W. Garrison, C. Andrew DeRyke, Daryl D. DePestel, Pamela A. Moise, Helio S. Sader
Publikováno v:
International Journal of Infectious Diseases, Vol 112, Iss , Pp 321-326 (2021)
ABSTRACT: Objectives: To report on the activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa isolates collected from hospitalized patients with pneumonia in US intensive care units (ICUs) between 2015 and 2018. Activity ag
Externí odkaz:
https://doaj.org/article/cf72f849d8a4498eace2fdbed29e04ca
Autor:
Kenneth P. Klinker, Levita K. Hidayat, C. Andrew DeRyke, Daryl D. DePestel, Mary Motyl, Karri A. Bauer
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 8 (2021)
The rapid evolution of resistance, particularly among Gram-negative bacteria, requires appropriate identification of patients at risk followed by administration of appropriate empiric antibiotic therapy. A primary tenet of antimicrobial stewardship p
Externí odkaz:
https://doaj.org/article/812fbac324e34437ad7980173a439e12
Autor:
Kenneth P. Klinker, Levita K. Hidayat, Eric Wenzler, Joan-Miquel Balada-Llasat, Mary Motyl, C. Andrew DeRyke, Karri A. Bauer
Publikováno v:
Antibiotics, Vol 11, Iss 5, p 660 (2022)
Antimicrobial resistance is a global public health threat, and gram-negative bacteria, such as Enterobacterales and Pseudomonas aeruginosa, are particularly problematic with difficult-to-treat resistance phenotypes. To reduce morbidity and mortality,
Externí odkaz:
https://doaj.org/article/8c31b56bde1d4b6386b74318a37f5b6c
Autor:
Sibylle H. Lob, Stephen P. Hawser, Fakhar Siddiqui, Irina Alekseeva, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 42:365-370
Autor:
Ignacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, Jiejun Du, Maria C Losada, Amanda Paschke, C Andrew DeRyke, Michael Wong, Erin H Jensen, Luke F Chen
Publikováno v:
Open Forum Infectious Diseases.
Background In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. This post hoc analysis was conduct